This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.
In addition to the positive results for the Keytruda plus Lenvima combination, Merck and Eisai added that Lenvima plus everolimus also showed improvements in PFS and ORR compared to Sutent. ... However, Lenvima plus everolimus did not demonstrate an
In a separate arm of the KEYNOTE-581 trial, the partner companies also evaluated Lenvima plus Novartis’ Afinitor (everolimus) in advanced RCC, with this combination also topping Sutent on PFS and
alive at this time-point compared to 18% of those treated only with the standard chemotherapy drug everolimus.
NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus everolimus would be the most appropriate alternative treatment.”. ... On that point, Baroness Morgan said that as everolimus with exemestane is
Around 70 people in England are currently prescribed everolimus for TSC-related kidney and brain tumours. ... NHS England estimates that a further 300 people in England will benefit from treatment with everolimus for TSC-related refractory epilepsy.
First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been
More from news
Approximately 8 fully matching, plus 66 partially matching documents found.
patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...